Literature DB >> 16598819

No evidence for dualism in function and receptors: PD-L2/B7-DC is an inhibitory regulator of human T cell activation.

Katharina Pfistershammer1, Christoph Klauser, Winfried F Pickl, Johannes Stöckl, Judith Leitner, Gerhard Zlabinger, Otto Majdic, Peter Steinberger.   

Abstract

The B7 family member programmed-death-1-ligand 2 (PD-L2/B7-DC) is a ligand for programmed-death-receptor 1 (PD-1), a receptor involved in negative regulation of T cell activation. Several independent studies have reported that PD-L2, however, can also potently costimulate murine T cells via an additional yet unidentified receptor. In this study, we evaluated the contribution of PD-L2 to the activation of human T cells using a novel system of engineered T cell stimulators that expresses membrane-bound anti-CD3 antibodies. Analyzing early activation markers, cytokine production and proliferation, we found PD-L2 to consistently inhibit T cell activation. PD-L2 inhibition affected CD4+ and CD8+ T cells and was not abrogated by costimulation via CD28. Blocking PD-1 reverted the inhibitory effect of PD-L2, demonstrating involvement of this pathway. In human T cells, we found no evidence for any of the costimulatory effects described for PD-L2 in murine systems. In line with our functional data that do not point to stimulatory PD-L2-ligands, we show that binding of PD-L2-immunoglobulin to activated human T cells is abrogated by PD-1 antibodies. Our results demonstrate that PD-L2 negatively regulates human T cell activation and thus might be a candidate molecule for immunotherapeutic approaches aimed to attenuate pathological immune responses.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16598819      PMCID: PMC2975063          DOI: 10.1002/eji.200535344

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  36 in total

1.  B7S1, a novel B7 family member that negatively regulates T cell activation.

Authors:  Durbaka V R Prasad; Sabrina Richards; Xoi Muoi Mai; Chen Dong
Journal:  Immunity       Date:  2003-06       Impact factor: 31.745

2.  B7x: a widely expressed B7 family member that inhibits T cell activation.

Authors:  Xingxing Zang; P'ng Loke; Jayon Kim; Kenneth Murphy; Rebecca Waitz; James P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-14       Impact factor: 11.205

3.  PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells.

Authors:  Yvette E Latchman; Spencer C Liang; Yin Wu; Tatyana Chernova; Raymond A Sobel; Martina Klemm; Vijay K Kuchroo; Gordon J Freeman; Arlene H Sharpe
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-12       Impact factor: 11.205

4.  Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis.

Authors:  Nancy Rodig; Timothy Ryan; Jessica A Allen; Hong Pang; Nir Grabie; Tatyana Chernova; Edward A Greenfield; Spencer C Liang; Arlene H Sharpe; Andrew H Lichtman; Gordon J Freeman
Journal:  Eur J Immunol       Date:  2003-11       Impact factor: 5.532

5.  Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains.

Authors:  Peter Steinberger; Otto Majdic; Sophia V Derdak; Katharina Pfistershammer; Stefanie Kirchberger; Christoph Klauser; Gerhard Zlabinger; Winfried F Pickl; Johannes Stöckl; Walter Knapp
Journal:  J Immunol       Date:  2004-02-15       Impact factor: 5.422

6.  The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses.

Authors:  Woong-Kyung Suh; Beata U Gajewska; Hitoshi Okada; Matthew A Gronski; Edward M Bertram; Wojciech Dawicki; Gordon S Duncan; Jacob Bukczynski; Suzanne Plyte; Andrew Elia; Andrew Wakeham; Annick Itie; Stephen Chung; Joan Da Costa; Sudha Arya; Tom Horan; Pauline Campbell; Kevin Gaida; Pamela S Ohashi; Tania H Watts; Steven K Yoshinaga; Mark R Bray; Manel Jordana; Tak W Mak
Journal:  Nat Immunol       Date:  2003-08-17       Impact factor: 25.606

7.  Duplication of primate and rodent B7-H3 immunoglobulin V- and C-like domains: divergent history of functional redundancy and exon loss.

Authors:  Vincent Ling; Paul W Wu; Vikki Spaulding; Jan Kieleczawa; Deborah Luxenberg; Beatriz M Carreno; Mary Collins
Journal:  Genomics       Date:  2003-09       Impact factor: 5.736

8.  Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction.

Authors:  Shengdian Wang; Jürgen Bajorath; Dallas B Flies; Haidong Dong; Tasuku Honjo; Lieping Chen
Journal:  J Exp Med       Date:  2003-04-28       Impact factor: 14.307

9.  Cooperative B7-1/2 (CD80/CD86) and B7-DC costimulation of CD4+ T cells independent of the PD-1 receptor.

Authors:  Tahiro Shin; Gene Kennedy; Kevin Gorski; Haruo Tsuchiya; Haruhiko Koseki; Miyuki Azuma; Hideo Yagita; Lieping Chen; Jonathan Powell; Drew Pardoll; Franck Housseau
Journal:  J Exp Med       Date:  2003-07-07       Impact factor: 14.307

10.  B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism.

Authors:  Xingluo Liu; Jian Xin Gao; Jing Wen; Lijie Yin; Ou Li; Tao Zuo; Thomas F Gajewski; Yang-Xin Fu; Pan Zheng; Yang Liu
Journal:  J Exp Med       Date:  2003-06-16       Impact factor: 14.307

View more
  24 in total

1.  Direct stimulation of T lymphocytes by immunosomes: virus-like particles decorated with T cell receptor/CD3 ligands plus costimulatory molecules.

Authors:  Sophia V Derdak; Hans J Kueng; Victoria M Leb; Alina Neunkirchner; Klaus G Schmetterer; Edith Bielek; Otto Majdic; Walter Knapp; Brian Seed; Winfried F Pickl
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-21       Impact factor: 11.205

2.  Fluorescence tagging and inducible depletion of PD-L2-expressing B-1 B cells in vivo.

Authors:  Rebecca A Lee; Changchuin Mao; Hung Vo; Wenda Gao; Xuemei Zhong
Journal:  Ann N Y Acad Sci       Date:  2015-08-20       Impact factor: 5.691

3.  Human tolerogenic dendritic cells produce IL-35 in the absence of other IL-12 family members.

Authors:  Karen O Dixon; Sandra W van der Kooij; Dario A A Vignali; Cees van Kooten
Journal:  Eur J Immunol       Date:  2015-06       Impact factor: 5.532

4.  ILDR2 Is a Novel B7-like Protein That Negatively Regulates T Cell Responses.

Authors:  Iris Hecht; Amir Toporik; Joseph R Podojil; Ilan Vaknin; Gady Cojocaru; Anat Oren; Elizabeta Aizman; Spencer C Liang; Ling Leung; Yosef Dicken; Amit Novik; Nadav Marbach-Bar; Aziza Elmesmari; Clare Tange; Ashley Gilmour; Donna McIntyre; Mariola Kurowska-Stolarska; Kay McNamee; Judith Leitner; Shirley Greenwald; Liat Dassa; Zurit Levine; Peter Steinberger; Richard O Williams; Stephen D Miller; Iain B McInnes; Eyal Neria; Galit Rotman
Journal:  J Immunol       Date:  2018-02-05       Impact factor: 5.422

5.  Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice.

Authors:  W Joost Lesterhuis; Cornelis J A Punt; Stanleyson V Hato; Dagmar Eleveld-Trancikova; Bastiaan J H Jansen; Stefan Nierkens; Gerty Schreibelt; Annemiek de Boer; Carla M L Van Herpen; Johannes H Kaanders; Johan H J M van Krieken; Gosse J Adema; Carl G Figdor; I Jolanda M de Vries
Journal:  J Clin Invest       Date:  2011-07-18       Impact factor: 14.808

6.  PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome.

Authors:  Joseph M Obeid; Gulsun Erdag; Mark E Smolkin; Donna H Deacon; James W Patterson; Leiping Chen; Timothy N Bullock; Craig L Slingluff
Journal:  Oncoimmunology       Date:  2016-09-20       Impact factor: 8.110

7.  Fluorosomes: a convenient new reagent to detect and block multivalent and complex receptor-ligand interactions.

Authors:  Hans J Kueng; Calin Manta; Daniela Haiderer; Victoria M Leb; Klaus G Schmetterer; Alina Neunkirchner; Ruth A Byrne; Clemens Scheinecker; Peter Steinberger; Brian Seed; Winfried F Pickl
Journal:  FASEB J       Date:  2010-01-07       Impact factor: 5.191

8.  Fusion protein of mutant B7-DC and Fc enhances the antitumor immune effect of GM-CSF-secreting whole-cell vaccine.

Authors:  Masatsugu Kojima; Satoshi Murata; Eiji Mekata; Katsushi Takebayashi; Elizabeth M Jaffee; Tohru Tani
Journal:  J Immunother       Date:  2014-04       Impact factor: 4.456

9.  B7-H3 is a potent inhibitor of human T-cell activation: No evidence for B7-H3 and TREML2 interaction.

Authors:  Judith Leitner; Christoph Klauser; Winfried F Pickl; Johannes Stöckl; Otto Majdic; Anaïs F Bardet; David P Kreil; Chen Dong; Tomohide Yamazaki; Gerhard Zlabinger; Katharina Pfistershammer; Peter Steinberger
Journal:  Eur J Immunol       Date:  2009-07       Impact factor: 5.532

10.  TCRαβ/CD3 disruption enables CD3-specific antileukemic T cell immunotherapy.

Authors:  Jane Rasaiyaah; Christos Georgiadis; Roland Preece; Ulrike Mock; Waseem Qasim
Journal:  JCI Insight       Date:  2018-07-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.